About Pantetheine hydrolase VNN2
Pantetheine hydrolase VNN2 (VNN2) is a protein
from Homo sapiens identified by UniProt accession
O95498, 520 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Pantetheine hydrolase VNN2 |
| UniProt accession | O95498 |
| Gene | VNN2 |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- vitamin B12 deficiency · score 0.21
- inflammatory bowel disease · score 0.13
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- cortical surface area measurement · score 0.09
- heel bone mineral density · score 0.09
- electrocardiography · score 0.09
- bone density · score 0.08
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95498-F1 | alphafold | PREDICTED | 91.69 | — |
Amino-acid sequence (520 residues)
MVTSSFPISV AVFALITLQV GTQDSFIAAV YEHAVILPNK TETPVSQEDA LNLMNENIDI LETAIKQAAE QGARIIVTPE DALYGWKFTR ETVFPYLEDI PDPQVNWIPC QDPHRFGHTP VQARLSCLAK DNSIYVLANL GDKKPCNSRD STCPPNGYFQ YNTNVVYNTE GKLVARYHKY HLYSEPQFNV PEKPELVTFN TAFGRFGIFT CFDIFFYDPG VTLVKDFHVD TILFPTAWMN VLPLLTAIEF HSAWAMGMGV NLLVANTHHV SLNMTGSGIY APNGPKVYHY DMKTELGKLL LSEVDSHPLS SLAYPTAVNW NAYATTIKPF PVQKNTFRGF ISRDGFNFTE LFENAGNLTV CQKELCCHLS YRMLQKEENE VYVLGAFTGL HGRRRREYWQ VCTLLKCKTT NLTTCGRPVE TASTRFEMFS LSGTFGTEYV FPEVLLTEIH LSPGKFEVLK DGRLVNKNGS SGPILTVSLF GRWYTKDSLY SSCGTSNSAI TYLLIFILLM IIALQNIVML
Explore Pantetheine hydrolase VNN2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets